Abvacc is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. AbVacc’s pipeline includes candidates for prevention and treatment of bacterial and viral infections. The main focus for the bacterial program is staphylococcal infections, by targeting a variety of virulence factors such as toxins and critical enzymes produced by S. aureus. AbVacc’s S. aureus vaccine (IBT-V02), developed for prevention of recurrent skin and soft tissues infection, was licensed to Limmatech in 2023 and has entered the clinic.